Puma Biotechnology (PBYI)
(Delayed Data from NSDQ)
$5.02 USD
+0.14 (2.87%)
Updated Apr 26, 2024 04:00 PM ET
After-Market: $5.01 -0.01 (-0.20%) 7:58 PM ET
4-Sell of 5 4
A Value A Growth C Momentum A VGM
Fundamental Charts
About Cash from Investing (TTM)
The company's trailing twelve month (TTM) Cash from Investing is the sum of the company's past 12 months cash position resulting from any gains or losses from investments in the financial markets, operating activities, and changes resulting from amounts spent on investments in capital assets such as plant and equipment. When evaluating the Cash from Investing value, it is important to consider each of the various activities which contribute to the overall change in cash position. A company can have a negative cash flow from investing and have a positive cash from Cash from operations or financing.
PBYI 5.02 +0.14(2.87%)
Will PBYI be a Portfolio Killer in April?
Zacks Investment Research is releasing its prediction for PBYI based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for PBYI
What's in Store for Puma Biotechnology (PBYI) in Q1 Earnings?
Earnings Preview: Puma Biotech (PBYI) Q1 Earnings Expected to Decline
PBYI: What are Zacks experts saying now?
Zacks Private Portfolio Services
Puma Biotech (PBYI) Stock Dips While Market Gains: Key Facts
Puma Biotechnology (PBYI) Soars 14.0%: Is Further Upside Left in the Stock?
FDA Lifts Clinical Hold on Iovance's (IOVA) Lung Cancer Study
Other News for PBYI
PBYI Crosses Above Average Analyst Target
7 Stocks Under $15 Predicted to Boom in the Next 2 Years
Puma Biotechnology to Host Conference Call to Discuss First Quarter 2024 Financial Results
Puma Biotechnology Reports Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)
PBYI Crosses Above Average Analyst Target